Ceva launches new spironolactone, PRILACTONE NEXT

Ceva Animal Health has launched a new and improved spironolactone, PRILACTONE NEXT, for the treatment of congestive heart failure caused by degenerative mitral valve disease in dogs.

PRILACTONE NEXT is replacing the popular spironolactone products PRILACTONE and TEMPORA, which will be discontinued, and joins Ceva’s extensive cardiology range which also includes CARDALIS, LIBEO and NELIO.

PRILACTONE NEXT is available in three presentations of 10mg, 50mg and 100mg. It comes in easy break, chewable tablets to more easily achieve the required dose; the 10mg tablet has a two-way split for a dog between 2.5kg and 5kg, while the 50mg and 100mg tablets have a four-way patented clover-shaped design with the 50mg for dogs between 18.1kg and 25kg and 100mg for dogs between 37.6kg and 50kg.  PRILACTONE NEXT is available in handy boxes of three blisters of 10 tablets for the 10mg and 50mg presentations and three blisters of eight tablets for the 100mg presentation for easy dispensing and storage in practice.

Nicola Barclay, product manager at Ceva Animal Health, comments: “PRILACTONE NEXT is an improved, easy to administer spironolactone that enables owners to accurately treat their pets and will further enhance our existing cardiology range.”

For further information on Ceva’s cardiology range, including PRILACTONE NEXT, CARDALIS, LIBEO and NELIO, please contact your local Ceva Animal Health territory manager.